Navigation Links
Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators
Date:5/18/2009

LA JOLLA, Calif., May 18 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has further expanded the Company's executive team with the addition of Pratik Multani, M.D., M.S., as Vice President of Clinical Development. With more than a decade of clinical development experience, Dr. Multani will lead Fate Therapeutics' upcoming clinical trials of Stem Cell Modulators (SCMs), small molecules and biologics that guide cell fate for therapeutic purposes. SCMs can potentially be applied in many areas, including regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

"Fate Therapeutics has been singularly focused on interrogating adult stem cell and induced pluripotent stem cell biology to find small molecule and biologic drug candidates that can modulate cell fate to develop tomorrow's medicines," said Paul Grayson, President and CEO of Fate Therapeutics. "As we are rapidly preparing to advance the Company's first drug candidate into clinical trials, Dr. Multani's successful clinical development experience and distinguished medical training will be a tremendous asset to drive our clinical programs forward."

Fate Therapeutics is utilizing its adult stem cell biology engine and induced pluripotent stem (iPS) cell technology platform to develop SCMs that can direct adult stem cell proliferation and function. Adult stem cells are naturally-occurring cells found in almost all tissues or organs in the body and are primarily responsible for maintaining and repairing their native tissue. An adult stem cell has unique properties, in that it can renew itself and differentiate to become some or all of the major specialized cell types of the particular tissue or organ in which it is found. The discovery of a number of conserved mechanisms from developmental biology and tissue repair has
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
2. Nile Therapeutics Reports 2009 First Quarter Financial Results
3. Oxygen Biotherapeutics, Inc. Signs Cooperative Research and Development Agreement With Naval Medical Research Center and Walter Reed Army Institute of Research
4. Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results
5. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
6. Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
7. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2009 Financial Results on Wednesday, May 13th, at 4:30 P.M. EST
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $20 Million of Common Stock and Warrants
9. Cell Therapeutics, Inc. Intends to Offer to Exchange up to $89.2 Million of its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
10. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
11. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2009)... skin,s surface, bacteria are abundant, diverse an...arch at the University of California, San Diego Sc...a living on the skin surface trigger a pathway tha... "These germs are actually good for us," said Ric...pediatrics, chief of UCSD,s Division of Dermatolog...
(Date:11/22/2009)... The holiday season is filled wit... both fun and joyous. It can also be stressful and...ion of stress, fatigue, and high fat foods -- fact...cer. That,s why the National Foundation for Cancer... that can help ensure a happier, more healthful ho...
(Date:11/21/2009)... , "This bill provides for an unprecedented e...lth care about if it is not for preserving and pro... must be defeated." Charmaine Yoest ,, WASHI...s United for Life Action President and CEO Dr. Cha...nate by releasing the following statement: ,, ...
(Date:11/21/2009)... NH based medical credentialing s...its industry to form a partnerhsip with Amerinet, ...his partnership will help to transform quality car... (Vocus) November 21, 2009 -- ISG Group, L...nced a new agreement with Amerinet Inc., a leading...
(Date:11/21/2009)... Linwood Group ask whether there ...be measured? , London, UK... that with up to one in three of the adult UK popu... developing alcohol-related liver disease*, it is ...ng to rehabilitation programmes and residential ce...
Breaking Medicine News(10 mins):Health News:Surface bacteria maintain skin's healthy balance 2Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 2Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 3Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4
...ity, Continued Growth Seen in Election Results , ...owth and growing influence for the nation,s larges... nurses, members of the California Nurses Associat...s and other incumbent members of the CNA/NNOC Boar...
... ANGELES, May 5 Colgate and the Hispanic Dental,A...Salud Bucal: Un Mundo de,Sonrisas Saludables (Oral...rt,of an ongoing commitment to quality oral care a...t for untreated dental caries among,children, acco...
...ON CITY, N.J., May 5 Colgate and the Hispanic Den...e la Salud Bucal: Un Mundo de,Sonrisas Saludables ...as part,of an ongoing commitment to quality oral c...ighest for untreated dental caries among,children,...
... duties June 1 at ADA Chicago Headquarters...D.M.D., M.P.H, of Medford, Mass., has been selecte...Association to serve as the next ADA Executive Dir...announcement marked the end of an 11-month search ...
...UM, Md., May 5 Dialysis Corporation of America (N...r the first quarter of 2009. , , , , ... Operating revenues for the first quarter of...quarter of 2009 compared to $1.3 million for the s...
...ds rate as high as 14.7 percent in one Minnesota c... Though dyslexia and attention-deficit disorder ar... inability to write properly -- strikes a signific... an epidemiologist at the Mayo Clinic and lead aut...
Other Medicine News:Health News:CNA/NNOC Re-Elects Council of Presidents 2Health News:Colgate Bright Smiles, Bright Futures(R) Kids' Initiative Visits Los Angeles 2Health News:Colgate Bright Smiles, Bright Futures(R) Kids' Initiative Visits Union City, NJ 2Health News:Dr. Kathleen O'Loughlin Named American Dental Association Executive Director 2Health News:Dr. Kathleen O'Loughlin Named American Dental Association Executive Director 3Health News:Dialysis Corporation of America Reports First Quarter 2009 Results 2Health News:Dialysis Corporation of America Reports First Quarter 2009 Results 3Health News:Dialysis Corporation of America Reports First Quarter 2009 Results 4Health News:Dialysis Corporation of America Reports First Quarter 2009 Results 5Health News:Dialysis Corporation of America Reports First Quarter 2009 Results 6Health News:Dialysis Corporation of America Reports First Quarter 2009 Results 7Health News:Dialysis Corporation of America Reports First Quarter 2009 Results 8Health News:Writing Disorder May Be Common Among Kids 2
(Date:11/20/2009)... Escalon Medical Corp. (N...fiscal first quarter ended September 30, 2009. ,... revenue decreased approximately $234,000, or 2.7%...d September 30, 2009 as compared to the same perio...eased net revenue of $8,434,000 compared with $8,6...
(Date:11/20/2009)... 20 /PRNewswire-FirstCall/ -- Landauer, Inc. (...scal fourth quarter and full year of 2009 pre-mark... will host a conference call for investors on Tues...Investors may access the live call by dialing 877-... 480-629-9835 (international callers), or by visit...
(Date:11/20/2009)...20 Reportlinker.com announces that...catalogue. ,, Pipettes & Pipettors - A Glo...inker.com/p0164373/Pipettes--Pipettors---A-Global-...utm_medium=pr&utm_campaign=prnewswire ,, ...part of any research laboratory. Large-scale appli...
Breaking Medicine Technology:Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 5976 1VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 5976 2VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 5976 3VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 5976 4Company Appoints New SVP Marketing for PBM Business 5974 1Company Appoints New SVP Marketing for PBM Business 5974 2Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascents Neurogenesis Platform 5972 1Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascents Neurogenesis Platform 5972 2
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: